| Symbol | TTRX |
|---|---|
| Name | TURN THERAPEUTICS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 250 N. WESTLAKE BLVD.,WESTLAKE VILLAGE, WESTLAKE VILLAGE, California, 91362, United States |
| Telephone | +1 818 564-4011 |
| Fax | — |
| — | |
| Website | https://turntherapeutics.com/ |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0002023016 |
| Description | Turn Therapeutics is a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process commercially referred to as PermaFusion enables stable suspension of polar watersoluble active pharmaceutical ingredients APIs in oilbased carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events. Our proprietary platform has been validated across multiple FDA cleared medical devices. Our primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Additional info from NASDAQ: |
(30% Negative) TURN THERAPEUTICS INC. (TTRX) Reports Q3 2026 Financial Results
Read moreTurn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
Read more(80% Positive) TURN THERAPEUTICS INC. (TTRX) Announces Enrollment Update for resulted Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreTurn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
Read moreTurn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
Read moreDirector Dewhurst Martin William 🟢 acquired 71.7K shares (1 derivative) of Turn Therapeutics Inc. (TTRX) at $5.75 Transaction Date: Jun 04, 2026 | Filing ID: 066395
Read moreDirector Gengos Andrew 🟢 acquired 95.0K shares (1 derivative) of Turn Therapeutics Inc. (TTRX) at $5.75 Transaction Date: Jun 04, 2026 | Filing ID: 066394
Read moreDirector GOLDEN ARTHUR F 🟢 acquired 89.6K shares (1 derivative) of Turn Therapeutics Inc. (TTRX) at $5.75 Transaction Date: Jun 04, 2026 | Filing ID: 066393
Read moreDirector Kester Kent Edward 🟢 acquired 83.3K shares (1 derivative) of Turn Therapeutics Inc. (TTRX) at $5.75 Transaction Date: Jun 04, 2026 | Filing ID: 066391
Read more(90% Positive) TURN THERAPEUTICS INC. (TTRX) Announces Enrollment Update for occur Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read more